Athersys, Inc. (ATHX) News
Filter ATHX News Items
ATHX News Results
|Loading, please wait...|
ATHX News Highlights
- For ATHX, its 30 day story count is now at 6.
- Over the past 6 days, the trend for ATHX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ARDS are the most mentioned tickers in articles about ATHX.
Latest ATHX News From Around the Web
Below are the latest news stories about Athersys Inc that investors may wish to consider to help them evaluate ATHX as an investment opportunity.
Every investor in Athersys, Inc. ( NASDAQ:ATHX ) should be aware of the most powerful shareholder groups. Insiders...
Athersys, Inc. (ATHX) Q4 Full Year 2020 Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Karen Hunady – Director-Corporate Communications and Investor Relations B.J. Lehmann – Interim Chief Executive Officer Ivor Macleod – Chief Financial Officer Conference Call Participants Greg Harrison – Bank of America David Hoang...
Ladies and gentlemen, thank you for standing by, and welcome to the Athersys fourth-quarter and full-year 2020 results conference call. As Rob mentioned, I'm Karen Hunady, director of corporate communications and investor relations for Athersys.
Athersys (ATHX): FY GAAP EPS of -$0.11 beats by $0.32.Revenue of $1.27M (+337.9% Y/Y) beats by $0.99M.Press Release...
Athersys continues to develop large-scale manufacturing processes and advance MultiStem cell therapy clinical trials for stroke, ARDS, and trauma.
OrganiGram (NASDAQ:OGI) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Institutional & Insider Ownership 10.8% of OrganiGram shares are held by institutional investors. Comparatively, 27.9% of Athersys […]
Regenerative Medicine Market Is Expected To Exhibit 32.2% CAGR By 2023 | Medtronic Plc., Athersys, Inc.
Rise in adoption of stem cell technology, rise in application of nanotechnology, increased prevalence of chronic diseases and trauma emergencies, and increasing technological advancements in medical equipment technology are expected to propel the growth of the global regenerative medicine market. Download
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys
Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.